Compare ONTF & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONTF | ORGO |
|---|---|---|
| Founded | 1998 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 347.2M | 348.6M |
| IPO Year | 2021 | 2016 |
| Metric | ONTF | ORGO |
|---|---|---|
| Price | $8.11 | $2.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $8.10 | ★ $8.50 |
| AVG Volume (30 Days) | 986.7K | ★ 1.3M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 32.67 | ★ 1600.00 |
| EPS | N/A | ★ N/A |
| Revenue | $139,312,000.00 | ★ $564,169,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.51 | $26.27 |
| P/E Ratio | ★ N/A | $16.73 |
| Revenue Growth | N/A | ★ 17.04 |
| 52 Week Low | $4.70 | $2.21 |
| 52 Week High | $8.11 | $7.08 |
| Indicator | ONTF | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 67.87 | 43.03 |
| Support Level | $7.84 | $2.26 |
| Resistance Level | N/A | $2.60 |
| Average True Range (ATR) | 0.02 | 0.16 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 88.89 | 46.38 |
ON24 Inc provides a cloud-based intelligent engagement platform that combines experiences with personalization and content, to enable sales and marketing organizations to capture and act on connected insights at scale. The company's platform offers a portfolio of interactive and hyper-personalized digital experience products that create and capture actionable, real-time data at scale from millions of professionals to provide businesses with buying signals and behavioral insights to efficiently convert prospects into customers. It provides solutions to Financial services, Life Sciences, Life sciences, Insurance, Technology, Associations, and Others. Geographically, the company derives maximum revenue from United States, and also has its presence in EMEA and Other Countries.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.